Regulatory Disputes with HHS: When to Negotiate and When to Litigate

Overview



Access the takeaways here.

For healthcare and life sciences companies, regulatory disputes with the U.S. Department of Health and Human Services (HHS) and its operating divisions can present significant economic costs and reputational risks. Efficient resolutions of such disputes are always preferable and require an understanding of the law, the institutional relationships between the relevant HHS operating division and other parts of the Executive Branch and agency personnel. When a company cannot reach an efficient resolution through negotiation and litigation is the only option, the company must vindicate its rights in a principled way that mitigates reputation risks.

Arm in-house healthcare and life sciences lawyers with the knowledge they need to navigate regulatory disputes with HHS and its operating divisions. Learn from former senior government officials:

  • The basics of the governing legal framework, which is the Administrative Procedure Act
  • Best practices for dispute resolution through advocacy at the division level and department levels and through litigation
  • A Case Study: APA negotiation and litigation approaches with one key HHS operating division, the U.S. Food and Drug Administration (FDA)
  • Regulatory areas that may give rise to disputes in the Biden Administration

Registration Information

12:00 pm – 1:00 pm EST

Dig Deeper

New York City, NY / McDermott Event / October 20, 2022

2022 Hospitals & Health Systems Innovation Summit

Paris, France / McDermott Event / October 18, 2022

European Healthcare & Life Sciences Symposium

London, United Kingdom / McDermott Event / September 29, 2022

HPE Europe 2022

Washington, DC / Speaking Engagements / September 19-20, 2022

National Advertising Division's Annual Conference

Arlington, VA / National Vaccine Law Conference / September 15-16, 2022

National Vaccine Law Conference

Get In Touch